LMDXW Projected Dividend Yield
Wt Exp 09/28/2026/LumiraDx Ltd ( NASDAQ : LMDXW )LumiraDx is a point of care diagnostic company. Co.'s existing test menu includes its International Normalized Ratio test for monitoring warfarin therapy, its Glycated Hemoglobin test for monitoring diabetes, its NT-proBNP test for aiding in the diagnosis of heart failure, its D-Dimer test for aiding in diagnosis and exclusion of venous thromboembolism, and its C-Reactive Protein test which measures a universal biomarker of infection and inflammation. Co. has developed four rapid COVID-19 molecular reagent testing kits for use on open molecular systems, SARS-CoV-2 RNA STAR, SARS-CoV-2 RNA STAR Complete, SARS-CoV-2 & Flu A/B RNA STAR Complete and Dual-Target SARS CoV-2 STAR Complete. 20 YEAR PERFORMANCE RESULTS |
LMDXW Dividend History Detail LMDXW Dividend News LMDXW Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |